Noninvasive detection of complement activation through radiologic imaging

Advances in Experimental Medicine and Biology

Volumn 734, Issue , 2013, Pages 271-282

  Thurman, Joshua M ^a   Rohrer, Bärbel ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 2; ECULIZUMAB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; COMPLEMENT INHIBITOR; CONTRAST MEDIUM; RECOMBINANT PROTEIN;

AUTOIMMUNITY; COMPLEMENT ACTIVATION; CONFERENCE PAPER; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMMUNOFLUORESCENCE MICROSCOPY; INFLAMMATORY DISEASE; INNATE IMMUNITY; LUPUS LIKE SYNDROME; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RETINA MACULA AGE RELATED DEGENERATION; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AUTOIMMUNE DISEASE; COMPLEMENT DISORDER; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; KIDNEY CORTEX; KIDNEY DISEASE; LUPUS LIKE KIDNEY DISEASE; PHYSICAL CHEMISTRY;

EID: 84934444469     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4118-2_19     Document Type: Conference Paper

References (53)

1. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G et al (2010) The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29:95-1122
2. Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S (2005) Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 115:2444-24533
3. Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S (2008) Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 180: 1231-12388
4. Badar A, DeFreitas S, McDonnell JM, Yahya N, Thakor D, Razavi R, Smith R, Sacks S, Mullen GE (2011) Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complement. PLoS One 6:e182755
5. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH et al (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123(Pt 11):2321-23377
6. Barrera P, Oyen WJ, Boerman OC, van Riel PL (2003) Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis 62:825-8288
7. Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, Haycock GB, Hicks J (1983) Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 74:175-1922
8. de Cordoba SR, de Jorge EG (2008) Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 151:1-133
9. di Belgiojoso GB, Tarantino A, Durante A, Guerra L (1975) Complement deposition in glomerular diseases. Proc Eur Dial Transplant Assoc 11:515-5211
10. Dodds AW, Ren XD, Willis AC, Law SK (1996) The reaction mechanism of the internal thioester in the human complement component C4. Nature 379:177-1799
11. Elward K, Griffiths M, Mizuno M, Harris CL, Neal JW, Morgan BP, Gasque P (2005) CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 280:36342-363544
12. Fishelson Z, Horstmann RD, Muller-Eberhard HJ (1987) Regulation of the alternative pathway of complement by pH. J Immunol 138:3392-33955
13. Gilbert HE, Aslam M, Guthridge JM, Holers VM, Perkins SJ (2006) Extended fl exible linker structures in the complement chimaeric conjugate CR2-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy. J Mol Biol 356:397-4122
14. Gratz S, Rennen HJ, Boerman OC, Oyen WJ, Corstens FH (2001) Rapid imaging of experimental colitis with (99m) Tc-interleukin-8 in rabbits. J Nucl Med 42:917-9233
15. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB (1999) C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 190:1733-17400
16. He C, Imai M, Song H, Quigg RJ, Tomlinson S (2005) Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for c5b-9. J Immunol 174:5750-57577
17. Hebert LA, Cosio FG, Neff JC (1991) Diagnostic significance of hypocomplementemia. Kidney Int 39:811-8211
18. Hebert LA, Cosio FG, Birmingham DJ (2001) Complement and complement regulatory proteins in renal disease. In: Neilson EG, Couser WG (eds) Immunologic renal diseases. Lippincott Williams & Wilkins, Philadelphia, pp 367-3933
19. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S (2008) A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 181:8068-80766
20. Jaffer FA, Weissleder R (2005) Molecular imaging in the clinical arena. JAMA 293:855-8622
21. Janssen BJ, Christodoulidou A, McCarthy A, Lambris JD, Gros P (2006) Structure of C3b reveals conformational changes that underlie complement activity. Nature 444:213-2166
22. Josephson L, Lewis J, Jacobs P, Hahn PF, Stark DD (1988) The effects of iron oxides on proton relaxivity. Magn Reson Imaging 6:647-6533
23. Lucignani G (2009) Nanoparticles for concurrent multimodality imaging and therapy: the dawn of new theragnostic synergies. Eur J Nucl Med Mol Imaging 36:869-8744
24. Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM, Medsger TA Jr, Ramsey-Goldman R (1996) Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 39:1178-11888
25. McAteer MA, Sibson NR, von Zur Muhlen C, Schneider JE, Lowe AS, Warrick N, Channon KM, Anthony DC, Choudhury RP (2007) In vivo magnetic resonance imaging of acute brain in flammation using microparticles of iron oxide. Nat Med 13:1253-12588
26. Moll S, Miot S, Sadallah S, Gudat F, Mihatsch MJ, Schifferli JA (2001) No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int 59:160-1688
27. Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S (2000) Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol 11:700-7077
28. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M (2002) Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice de ficient in complement factor H. Nat Genet 31:424-4288
29. Pons F, Sanmarti R, Herranz R, Collado A, Piera C, Vidal-Sicart S, Munoz-Gomez J, Setoain J (1996) Scintigraphic evaluation of the severity of in flammation of the joints with 99TCm-HIG in rheumatoid arthritis. Nucl Med Commun 17:523-5288
30. Porcel JM, Ordi J, Castro-Salomo A, Vilardell M, Rodrigo MJ, Gene T, Warburton F, Kraus M, Vergani D (1995) The value of complement activation products in the assessment of systemic lupus erythematosus fl ares. Clin Immunol Immunopathol 74:283-2888
31. Ramos-Casals M, Campoamor MT, Chamorro A, Salvador G, Segura S, Botero JC, Yague J, Cervera R, Ingelmo M, Font J (2004) Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 13:777-7833
32. Ricker DM, Hebert LA, Rohde R, Sedmak DD, Lewis EJ, Clough JD (1991) Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 18:678-6855
33. Ricklin D, Lambris JD (2007) Complement-targeted therapeutics. Nat Biotechnol 25:1265-12755
34. Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nature Immunol 11:785-7977
35. Rohrer B, Long Q, Coughlin B, Wilson RB, Huang Y, Qiao F, Tang PH, Kunchithapautham K, Gilkeson GS, Tomlinson S (2009) A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of agerelated macular degeneration. Invest Ophthalmol Vis Sci 50:3056-30644
36. Rohrer B, Long Q, Coughlin B, Renner B, Huang Y, Kunchithapautham K, Ferreira VP, Pangburn MK, Gilkeson GS, Thurman JM et al (2010) A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol 703:137-1499
37. Roivainen A, Parkkola R, Yli-Kerttula T, Lehikoinen P, Viljanen T, Mottonen T, Nuutila P, Minn H (2003) Use of positron emission tomography with methyl-11C-choline and 2-18F- fl uoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 48:3077-30844
38. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256-12644
39. Sargsyan SA, Serkova NJ, Renner B, Hasebroock KM, Larsen B, Stoldt C, McFann K, Pickering MC, Thurman JM (2011) Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney Int, 81:152-1599
40. Sargsyan SA, Serkova NJ, Renner B, Hasebroock KM, Larsen B, Stoldt C, McFann K, Pickering MC, Thurman JM (2012) Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney Int, 81:152-1599
41. Schulze M, Pruchno CJ, Burns M, Baker PJ, Johnson RJ, Couser WG (1993) Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. Am J Pathol 142:179-1877
42. Serkova NJ, Renner B, Larsen BA, Stoldt CR, Hasebroock KM, Bradshaw-Pierce EL, Holers VM, Thurman JM (2010) Renal in flammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology 255:517-5266
43. Shubayev VI, Pisanic TR II, Jin S (2009) Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 61:467-4777
44. Signore A, Picarelli A, Annovazzi A, Britton KE, Grossman AB, Bonanno E, Maras B, Barra D, Pozzilli P (2003) 123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl Med Commun 24:305-3166
45. Song H, He C, Knaak C, Guthridge JM, Holers VM, Tomlinson S (2003) Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest 111:1875-18855
46. Swaak AJ, Groenwold J, Bronsveld W (1986) Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45:359-3666
47. Thurman JM, Renner B, Kunchithapautham K, Ferreira VP, Pangburn MK, Ablonczy Z, Tomlinson S, Holers VM, Rohrer B (2009) Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J Biol Chem 284:16939-169477
48. Vlaicu R, Rus HG, Niculescu F, Cristea A (1985) Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis 55:35-500
49. Walport MJ (2001) Complement. Second of two parts. N Engl J Med 344:1140-11444
50. Weis JJ, Tedder TF, Fearon DT (1984) Identi fication of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci USA 81:881-8855
51. Weller GE, Lu E, Csikari MM, Klibanov AL, Fischer D, Wagner WR, Villanueva FS (2003) Ultrasound imaging of acute cardiac transplant rejection with microbubbles targeted to intercellular adhesion molecule-1. Circulation 108:218-2244
52. West C (1998) Complement and glomerular diseases. In: Volanakis JE, Frank MM (eds) The human complement system in health and disease. Marcel Dekker, Inc., New York, pp 571-5966
53. Zhou J, Fonseca MI, Pisalyaput K, Tenner AJ (2008) Complement C3 and C4 expression in C1q suf ficient and de ficient mouse models of Alzheimer's disease. J Neurochem 106:2080-20922